HDFC Pharma and Healthcare Fund
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Growthvine rating: 3/5 — ranked #41 of 84 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹21.32 (as of 2026-08-21) |
|---|
| AUM | ₹2,940 Cr |
|---|
| Expense ratio | 1.68% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nikhil Mathur |
|---|
| Exit load | 1% for redemption within 30 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -15.07% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 104.4% of NIFTY Pharma's upside and 71.3% of its downside.
Market cap allocation
| Large cap | 27.4% |
|---|
| Mid cap | 37.5% |
|---|
| Small cap | 35.1% |
|---|
Concentration
| Top 5 holdings | 33.0% |
|---|
| Top 10 holdings | 51.8% |
|---|
| Total holdings | 37 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 9.7%
- Divis Laboratories Ltd. — 9.1%
- Max Healthcare Institute Limited — 4.8%
- Aster DM Healthcare Limited — 4.7%
- Lupin Ltd — 4.7%
- Cipla Ltd. — 4.6%
- Alkem Laboratories Limited — 3.7%
- ACUTAAS CHEMICALS LIMITED — 3.6%
- Anthem Biosciences Limited — 3.6%
- Neuland Laboratories Limited. — 3.4%
Top sectors
- Pharma & Biotech — 71.2%
- Healthcare — 28.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 23.7% | Q1 (Top) | #2 of 76 |
| 2025 | 1.2% | Q2 | #29 of 69 |
| 2024 | 50.3% | Q1 (Top) | #1 of 58 |